⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17235754 | 0.79 | — | — | |
| SCHEMBL1745352 | 0.74 | — | — | |
| SCHEMBL2083101 | 0.74 | ABAT (0.48) | — | |
| SCHEMBL2079668 | 0.74 | ABAT (0.48) | — | |
| SCHEMBL301495 | 0.73 | — | — | |
| SCHEMBL1203668 | 0.72 | ESR2 (0.35) | — | |
| SCHEMBL16028416 | 0.71 | — | — | |
| SCHEMBL16118871 | 0.71 | — | — | |
| SCHEMBL3627494 | 0.71 | — | — | |
| SCHEMBL30599788 | 0.70 | FAAH (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119119035-A | RIPK1 kinase target inhibitor and preparation method and application thereof | 中山大学 | 2024-12-13 | — | — | CN | claimed |
| CN-117069618-A | Method for preparing Abusitinib key intermediate by utilizing microchannel reactor | 常州制药厂有限公司 | 2023-11-17 | — | — | CN | claimed |
| EP-4178620-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12528786-B2 | Plasma kallikrein inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4665330-A1 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| CN-119119035-A | RIPK1 kinase target inhibitor and preparation method and application thereof | 中山大学 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024199341-A1 | FUSED POLYCYCLIC DERIVATIVE AND USE THEREOF | 浙江海正药业股份有限公司 | 2024-10-03 | — | — | WO | disclosed |
| WO-2024173196-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-08-22 | — | — | WO | disclosed |
| CN-117069618-A | Method for preparing Abusitinib key intermediate by utilizing microchannel reactor | 常州制药厂有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20230348428-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20150031627-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2013107291-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | WO | disclosed |
| WO-2013107405-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | WO | disclosed |
| US-20130190249-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190249-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-25 | — | — | US | disclosed |
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-12-16 | — | — | US | disclosed |
| EP-2234961-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009065406-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2009-05-28 | — | — | WO | disclosed |
| US-5036063-A | Penem derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-07-30 | — | — | US | disclosed |